Source: The Business Journals: Philadelphia

Chondrial Therapeutics: Exclusive: Bala Cynwyd company raises $25.8M

The six-year-old biopharm company's new drug candidate targets Friedreich's Ataxia, a progressive disease that affects multiple body systems.

Read full article »
Chondrial Therapeutics's Competitors | Chondrial Therapeutics's News | Chondrial Therapeutics's Financials
Stay up-to-date with the latest news on Chondrial Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Carole Ben-Maimon's photo - President & CEO of Chondrial Therapeutics

President & CEO

Carole Ben-Maimon

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on Chondrial Therapeutics